Wegovy
-
healthNew Study Links Wegovy to Nearly Fivefold Increase in Sudden Vision Loss Compared to Ozempic
Analysis of seven years of FDA data indicates Wegovy users face significantly higher risks of ischemic optic neuropathy compared to Ozempic patients.
-
healthGLP-1 Drugs Show Promise as Addiction 'Habit-Breakers'
New research suggests GLP-1 medications like Ozempic and Wegovy may significantly reduce addiction risks and substance-related deaths across various substances.
-
healthOzempic-Like Drugs Linked to Increased Bone and Joint Condition Risk
New study suggests GLP-1 medications like Ozempic may slightly elevate risks of osteoporosis, gout, and osteomalacia, prompting calls for bone health monitoring.
-
healthGLP-1 Drugs Linked to Increased Fracture, Osteoporosis, and Gout Risk in New Studies
New research suggests GLP-1 medications like Ozempic and Wegovy may elevate fracture risk and exacerbate osteoporosis and gout, particularly in older adults.
-
healthAnti-Obesity Drug Set for Drastic Price Drop Post-Patent
New study reveals blockbuster anti-obesity and diabetes drug, semaglutide, could cost as little as $3 per month to manufacture, offering hope for wider access.
-
healthWeight-Loss Drugs Show Promise in Heart Attack Recovery
New study reveals GLP-1 drugs may significantly improve recovery and reduce complications for heart attack patients, offering cardiovascular benefits beyond weight loss.
-
healthSemaglutide Shows Promise in Reversing Osteoarthritis Damage
New research suggests semaglutide, known for diabetes and weight loss, may reverse joint tissue damage in osteoarthritis by reprogramming cell metabolism.
-
healthBeware of Compounded GLP-1 Drugs: Risks and Realities
Understand the critical differences between FDA-approved and compounded GLP-1 medications. Protect your health from unregulated and potentially dangerous alternatives.